endpts.com·Apr 7, 2026
Merck and Terns Pharmaceuticals were involved in a $6.7 billion M&A deal that didn't go as expected, with Merck significantly reducing its offer.
This content highlights the volatility and unpredictability of mergers and acquisitions in the biotech sector, underscoring the importance of thorough due diligence and adaptive strategies for healthtech professionals considering investments or partnerships.